168 related articles for article (PubMed ID: 16921788)
1. [Changes in C-reactive protein levels induced by different application forms of estrogen replacement therapy].
Fait T; Vrablík M; Kostírová M; Trnková B
Cas Lek Cesk; 2006; 145(7):571-4; discussion 574. PubMed ID: 16921788
[TBL] [Abstract][Full Text] [Related]
2. Changes in hemostatic variables induced by estrogen replacement therapy: comparison of transdermal and oral administration in a crossover-designed study.
Fait T; Vrablik M; Zizka Z; Kostirova M
Gynecol Obstet Invest; 2008; 65(1):47-51. PubMed ID: 17713346
[TBL] [Abstract][Full Text] [Related]
3. Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: cross-over designed study.
Fait T; Vrablik M; Cibula D; Masata J; Hill M; Trnkova B
Neuro Endocrinol Lett; 2006 Oct; 27(5):665-8. PubMed ID: 17159824
[TBL] [Abstract][Full Text] [Related]
4. Effect of early estrogen replacement therapy on microvascular reactivity in patients after bilateral ovarectomy.
Prázný M; Fait T; Vrablik M
Neuro Endocrinol Lett; 2007 Aug; 28(4):496-501. PubMed ID: 17693976
[TBL] [Abstract][Full Text] [Related]
5. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
Post MS; Christella M; Thomassen LG; van der Mooren MJ; van Baal WM; Rosing J; Kenemans P; Stehouwer CD
Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1116-21. PubMed ID: 12730085
[TBL] [Abstract][Full Text] [Related]
6. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
Eilertsen AL; Høibraaten E; Os I; Andersen TO; Sandvik L; Sandset PM
Maturitas; 2005 Oct; 52(2):111-8. PubMed ID: 16186073
[TBL] [Abstract][Full Text] [Related]
7. [Changes of plasminogen activator inhibitor (PAI-1) during estrogen replacement therapy].
Zizka Z; Fait T; Vrablík M
Cas Lek Cesk; 2007; 146(11):874-7. PubMed ID: 18069215
[TBL] [Abstract][Full Text] [Related]
8. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins.
Vrablik M; Fait T; Kovar J; Poledne R; Ceska R
Metabolism; 2008 Aug; 57(8):1088-92. PubMed ID: 18640386
[TBL] [Abstract][Full Text] [Related]
9. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
10. Effects of intranasal 17beta-estradiol administration on serum bioactive interleukin-6 and C-reactive protein levels in healthy postmenopausal women.
Rachoń D; Suchecka-Rachoń K; Hak Ł; Myśliwska J
Menopause; 2006; 13(5):840-5. PubMed ID: 16894332
[TBL] [Abstract][Full Text] [Related]
11. Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma bradykinin level, and blood pressure of normotensive postmenopausal women.
Ichikawa J; Sumino H; Ichikawa S; Ozaki M
Am J Hypertens; 2006 Jul; 19(7):744-9. PubMed ID: 16814131
[TBL] [Abstract][Full Text] [Related]
12. Effect of oral or transdermal hormone replacement therapy on homocysteine levels: a randomized clinical trial.
Bruschi F; Dal Pino D; Fiore V; Parazzini F; Di Pace R; Cesana BM; Melotti D; Crosignani PG
Maturitas; 2004 May; 48(1):33-8. PubMed ID: 15223106
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy.
Maffei S; Mercuri A; Prontera C; Zucchelli GC; Vassalle C
Climacteric; 2006 Dec; 9(6):452-8. PubMed ID: 17085378
[TBL] [Abstract][Full Text] [Related]
14. Effects of postmenopausal hormone replacement therapy on body fat composition.
Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
[TBL] [Abstract][Full Text] [Related]
15. Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application.
Mueck AO; Genazzani AR; Samsioe G; Vukovic-Wysocki I; Seeger H
Menopause; 2007; 14(6):978-84. PubMed ID: 17595593
[TBL] [Abstract][Full Text] [Related]
16. Estrogen therapy effects on different vasoactive factors in recent postmenopausal healthy women.
Maffei S; Mercuri A; Zucchelli GC; Vassalle C
Int J Cardiol; 2006 Feb; 107(2):194-9. PubMed ID: 16412796
[TBL] [Abstract][Full Text] [Related]
17. The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy.
Ravn P; Warming L; Christgau S; Christiansen C
Bone; 2004 Nov; 35(5):1216-21. PubMed ID: 15542048
[TBL] [Abstract][Full Text] [Related]
18. Effects of hormone replacement therapy on insulin resistance and platelet function tests.
Saraç F; Saydam G; Sahin F; Oztekin K; Saygili F; Tüzün M; Yilmaz C
Med Princ Pract; 2009; 18(1):43-7. PubMed ID: 19060490
[TBL] [Abstract][Full Text] [Related]
19. [Oral or transdermal estrogen substitution therapy in climacteric?].
Runnebaum B; Salbach B; von Holst T
Geburtshilfe Frauenheilkd; 1994 Mar; 54(3):119-30. PubMed ID: 8188009
[TBL] [Abstract][Full Text] [Related]
20. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol.
Blumenfeld Z; Boulman N; Leiba R; Siegler E; Shachar S; Linn R; Levy Y
Scand J Clin Lab Invest; 2007; 67(3):257-63. PubMed ID: 17454839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
